lundi 16 décembre 2019

Onco Actu du 16 décembre 2019


4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Finding a Non-invasive Way to Predict Effectiveness of Cancer Therapy [SNMI]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



The American College of Medical Genetics and Genomics advises evaluating all breast cancer patients to determine the need for genetic testing [Vanderbilt University]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Lymph vessels on a chip reveal possible new drug target for lymphedema [Science]











5.10 TRAITEMENTS - ESSAIS



Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial [AACR]











Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases [EurekAlert!]











Digital clinical trials: creating a vision for the future [npj Digital Medicine]










5.12 IMMUNOTHÉRAPIES



Identifying the source of tumour-infiltrating T cells [Nature]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer [Transgene]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Roche's triplet involving Tecentriq clears the PFS bar for melanoma when added to BRAF/MEK combo [EndPoints]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Jury finds Gilead liable for $585M and big royalties in Kite CAR-T patent case [EndPoints]











Bristol-Myers wins $752 million in U.S. patent case against Gilead [Reuters]











5.2 PHARMA



New drug development: ‘It’s the ecosystem, stupid’ [STAT]










5.3 TRAITEMENTS - FDA, EMA, NICE...



CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer [Lilly]











CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma [Genmab]











Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019 [EMA]










5.6.7 ESMO - IMMUNOTHÉRAPIES



Gritstone posts 'one of the most potent immunogenic-responses for a neoantigen vaccine' [Fierece Biotech]











The QuIP Study Attempts to Harmonise the Use of TMB Panels [ESMO]











5.6.7.1 ESMO-IMMUNOTHÉRAPIES-PEMBROLIZUMAB



BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer [BioLineRx]











BL-8040, Pembrolizumab and Chemotherapy Deliver Promising Disease Control in Patients with Metastatic Pancreatic Adenocarcinoma [ESMO]











5.7.2 SABCS-DIVERS



Extended letrozole therapy improves disease-free survival (DFS) in postmenopausal women with HR+ breast cancer: 10-year results of NRG Oncology/NSABP B-42 trial [NRG Oncology]











Radiation of Just Part of the Breast Can Stop Cancer's Return [US News]











5.7.4 SABCS-ESSAIS



Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium [Halozyme]











HER2CLIMB and DESTINY-Breast01 Findings in Heavily Pretreated HER2-positive MBC [ESMO]











5.7.5 SABCS-BIOPSIES LIQUIDES



UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment [Genome Web]











New Data Emerges for Liquid Biopsy in Breast Cancer Residual Disease Detection [Genome Web]











Indiana University School of Medicine researchers use cutting-edge technology to predict which triple negative breast cancer patients may avoid recurrence and those who are at high-risk of relapse [Indiana University]











Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer [AACR]











Liquid biopsy may predict breast cancer recurrence [UPI]











5.7.6 SABCS-THS



Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women [AACR]










Breast cancer risk from menopause hormones may last decades [AP]











HRT containing oestrogen may cut the risk of post-menopausal women getting breast cancer - but pills with progesterone INCREASE the risk [MailOnLine]











5.7.7-SABCS-BIOMARQUEURS



Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type [AACR]











Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer [MD Anderson Cancer Center]











6.10 POLITIQUES



Tory landslide election victory sets U.K. on path to Brexit [Fierce Biotech]











UK election dashes scientists’ hopes of staying in the EU [Nature]











6.6 PUBLICATIONS



Elsevier deal with France disappoints open-access advocates [Science]